Treatment of colon cancer cells using the cytosine deaminase/5- fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90β phosphorylation

Molecular Cancer Therapeutics

Volumn 6, Issue 10, 2007, Pages 2747-2756

  Negroni, Luc ^a,b   Samson, Michel ^a   Guigonis, Jean Marie ^a   Rossi, Bernard ^a   Pierrefite Carle, Valérie ^a   Baudoin, Christian ^a,c  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; HEAT SHOCK PROTEIN 90; PROTEOME;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHEMOTHERAPY; COLON CANCER; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; GENE EXPRESSION; GENETIC ANALYSIS; IMMUNITY; IMMUNOGENICITY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; RAT; SUICIDE GENE THERAPY; TUMOR REGRESSION; UPREGULATION;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; CYTOSINE DEAMINASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUCYTOSINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HSP90 HEAT-SHOCK PROTEINS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEOME; RATS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 35848962534     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0040     Document Type: Article

References (50)

1. Lal S, Lauer UM, Niethammer D, Beck JF, Schlegel PG. Suicide genes: past, present and future perspectives. Immunol Today 2000;21:48-54.
2. Bateman AR, Harrington KJ, Melcher AA, Vile RG. Cancer gene therapy: developments to 2000. Expert Opin Investig Drugs 2000;9:2799-813.
3. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage oftumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994;91:8302-6.
4. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
5. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumor against itself. Immunology 2005;114:11-22.
6. Kianmanesh AR, Perrin H, Panis Y, et al. A "distant" bystander effect ofsuicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther 1997;8:1807-14.
7. Pierrefite-Carle V, Baque P, Gavelli A, et al. Regression of experimental liver tumor after distant intra-hepatic injection of cytosine deaminase-expressing tumor cells and 5-fluorocytosine treatment. Int J Mol Med 2000;5:275-8.
8. Pierrefite-Carle V, Gavelli A, Brossette N, et al. Re: Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst 2000;92:494-5.
9. Pierrefite-Carle V, Baque P, Gavelli A, et al. Subcutaneous or intrahepatic injection ofsu icide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats. Gut 2002;50:387-91.
10. Multhoff G. Heat shock proteins in immunity. Handb Exp Pharmacol 2006:279-304.
11. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185-94.
12. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 2002;100:4108-15.
13. Rajagopal D, Bal V, Mayor S, George A, Rath S. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules. Eur J Immunol 2006;36:828-41.
14. Kotsiopriftis M, Tanner JE, Alfieri C. Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes γδ T-cell proliferation in vitro. J Virol 2005;79:7255-61.
15. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 2005;15:565-7.
16. Zhao YG, Gilmore R, Leone G, Coffey MC, Weber B, Lee PW. Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein. J Biol Chem 2001;276:32822-7.
17. Martin F, Caignard A, Jeannin JF, Leclerc A, Martin M. Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int J Cancer 1983;32:623-7.
18. Valot B, Negroni L, Zivy M, Gianinazzi S, Dumas-Gaudot E. A mass spectrometric approach to identify arbuscular mycorrhiza-related proteins in root plasma membrane fractions. Proteomics 2006;6 Suppl 1:S145-55.
19. Castedo M, Hirsch T, Susin SA, et al. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 1996;157:512-21.
20. Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol 1983;54:58-119.
21. Patenaude A, Ven Murthy MR, Mirault ME. Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J Biol Chem 2004;279:27302-14.
22. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.
23. Friedman HS, Johnson SP, Colvin OM. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. Cancer Treat Res 2002;112:199-209.
24. Sladek NE. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat Res 2002;112:161-75.
25. Di Paolo A, Danesi R, Del Tacca M. Pharmacogenetics of neoplastic diseases: new trends. Pharmacol Res 2004;49:331-42.
26. Nyhan WL. Disorders of purine and pyrimidine metabolism. Mol Genet Metab 2005;86:25-33.
27. van Kuilenburg AB, Meinsma R, van Gennip AH. Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids 2004;23:1371-5.
28. Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 2005;24:425-39.
29. Seiler A, Visan A, Buesen R, Genschow E, Spielmann H. Improvement of an in vitro stem cell assay for developmental toxicity: the use of molecular endpoints in the embryonic stem cell test. Reprod Toxicol 2004;18:231-40.
30. Fellenberg J, Dechant MJ, Ewerbeck V, Mau H. Identification of drug-regulated genes in osteosarcoma cells. Int J Cancer 2003;105:636-43.
31. Fais S. A role for ezrin in a neglected metastatic tumor function. Trends Mol Med 2004;10:249-50.
32. Parlato S, Giammarioli AM, Logozzi M, et al. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism ofthe CD95 apoptotic pathway. EMBO J 2000;19:5123-34.
33. Luciani F, Molinari A, Lozupone F, et al. P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells oflymphoid origin. Blood 2002;99:641-8.
34. Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised model ofmultidrug resistance in brain. Cell Mol Neurobiol 2000;20:165-81.
35. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005;6:318-27.
36. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003;81:536-48.
37. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-24.
38. Mhawech P. 14-3-3 proteins - an update. Cell Res 2005;15:228-36.
39. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203-13.
40. Liu Y, Liu H, Han B, Zhang J. Identification of 14-3-3 as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006;66:3248-55.
41. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
42. Ecroyd H, Jones RC, Aitken RJ. Tyrosine phosphorylation of HSP-90 during mammalian sperm capacitation. Biol Reprod 2003;69:1801-7.
43. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006;23:607-18.
44. Beausoleil SA, Jedrychowski M, Schwartz D, et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 2004;101:12130-5.
45. Nousiainen M, Sillje HH, Sauer G, Nigg EA, Korner R. Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci U S A 2006;103:5391-6.
46. DeGiorgis JA, Jaffe H, Moreira JE, et al. Phosphoproteomic analysis of synaptosomes from human cerebral cortex. J Proteome Res 2005;4:306-15.
47. Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci U S A 2006;103:7159-64.
48. Lees-Miller SP, Anderson CW. Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J Biol Chem 1989;264:2431-7.
49. Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005;23:94-101.
50. Kumar Y, Khachane A, Belwal M, Das S, Somsundaram K, Tatu U. ProteoMod: a new tool to quantitate protein post-translational modifications. Proteomics 2004;4:1672-83.